BRCA1 and pancreatic neuroendocrine tumor: Last year, we reported successful treatment of a grade 3 pancreatic neuroendocrine tumor (PNET; Ki-67 index 40%) with 177Lu-dotatate (4 treatments) in a patient with a pathogenic, heterozygous BRCA1 germline mutation (c.68_69delAG).1 This patient initially received capecitabine and temozolomide (CAPTEM) with at best mixed response.